Shockwave Medical will pay up to $147 million for Neovasc.
Shockwave Medical announced today that it has inked an agreement to purchase all of Neovasc‘s issued and outstanding common shares. In January 2022, Neovasc recruited its first patient in a clinical trial of the Neovasc Reducer. The device was created by the business to alleviate angina symptoms in persons suffering from refractory angina. It was … Read more